These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 3698686)
1. Role of lymphocytotoxicity and staph-protein A assays in platelet donor selection. Bonacossa IA; Perchotte MR; Olchowecki JK; Schroeder ML Curr Stud Hematol Blood Transfus; 1986; (52):58-64. PubMed ID: 3698686 [No Abstract] [Full Text] [Related]
2. Comparison of three cross-match techniques to select platelet donors. Lymphocytotoxicity, platelet suspension immunofluorescence test, and enzyme-linked immunosorbent assay. Bowen TJ; Berman-Wong E; Dawson D; Herbut B; Smith L; Snider C; Hill L Curr Stud Hematol Blood Transfus; 1986; (52):47-57. PubMed ID: 3516584 [No Abstract] [Full Text] [Related]
3. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets. Levy L; Woodfield DG N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558 [TBL] [Abstract][Full Text] [Related]
8. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection. Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444 [TBL] [Abstract][Full Text] [Related]
9. Detection of platelet alloimmunity with a platelet-associated IgG assay. Myers TJ; Kim BK; Steiner M; Bishop J; Baldini MG J Lab Clin Med; 1981 Jun; 97(6):854-63. PubMed ID: 7014743 [TBL] [Abstract][Full Text] [Related]
10. Platelet crossmatching with Capture P: clinical relevance. Böck M; Heim MU; Schleich I; Weindler R; Wagner M; Mempel W Infusionstherapie; 1989 Aug; 16(4):183-5. PubMed ID: 2807565 [No Abstract] [Full Text] [Related]
12. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. Daly PA; Schiffer CA; Aisner J; Wiernik PH JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763 [TBL] [Abstract][Full Text] [Related]
13. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Brand A; van Leeuwen A; Eernisse JG; van Rood JJ Blood; 1978 May; 51(5):781-8. PubMed ID: 346088 [TBL] [Abstract][Full Text] [Related]
14. [Optimal donor selection and the effectiveness of platelet transfusion in cases refractory to platelet transfusion]. Iwanaga T; Tsubaki K; Horiuchi A; Fujikawa Y; Kanemitsu Y Rinsho Ketsueki; 1986 Jul; 27(7):1274-7. PubMed ID: 3784009 [No Abstract] [Full Text] [Related]
15. [Selection of compatible thrombocyte donors using a solid-phase immunoassay in polytransfused patients]. Bade L; Gerdes R; Keller E; Rogge T Beitr Infusionsther; 1988; 21():299-303. PubMed ID: 2462997 [No Abstract] [Full Text] [Related]
16. Matching of histocompatibility (HL-A) antigens for platelet transfusion. Mittal KK; Ruder EA; Green D Blood; 1976 Jan; 47(1):31-41. PubMed ID: 1244913 [TBL] [Abstract][Full Text] [Related]
17. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness]. Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359 [TBL] [Abstract][Full Text] [Related]
18. Detection of platelet antibodies using the platelet migration inhibition assay. Levine SJ; Brubaker DB Am J Clin Pathol; 1983 Jul; 80(1):43-8. PubMed ID: 6858964 [TBL] [Abstract][Full Text] [Related]